China Boosts HPV Vaccine Access for Indonesian Women
- A partnership between China and Indonesia is expanding access to the human papillomavirus (HPV) vaccine for women in Indonesia, addressing critical barriers to cervical cancer prevention in the...
- According to reporting from Xinhua, the initiative aims to provide a shot of hope for Indonesian women who face significant challenges in obtaining the vaccine.
- The importance of the vaccine is highlighted by local perspectives, such as that of Ita, an Indonesian mother, who stated that the HPV vaccine is very important for...
A partnership between China and Indonesia is expanding access to the human papillomavirus (HPV) vaccine for women in Indonesia, addressing critical barriers to cervical cancer prevention in the region.
According to reporting from Xinhua, the initiative aims to provide a shot of hope
for Indonesian women who face significant challenges in obtaining the vaccine. For many families in Indonesia, the availability and affordability of the HPV vaccine have remained formidable hurdles.
The importance of the vaccine is highlighted by local perspectives, such as that of Ita, an Indonesian mother, who stated that the HPV vaccine is very important for women in Indonesia because it can protect us from cervical cancer.
Public Health Context of HPV and Cervical Cancer
The effort to expand vaccine access aligns with broader global health strategies. The World Health Organization’s Global Strategy for Cervical Cancer Elimination has set a global target that 90% of girls should be vaccinated against HPV.
Cervical cancer is identified as one of the few cancers that can be eliminated through a combination of safe and effective vaccines, screening, and treatment.
The World Health Organization generally recommends HPV vaccination for girls aged 9 to 14 years. Vaccinating individuals before they are exposed to the virus is considered the most cost-effective strategy and provides the highest level of protection.
Regional Trends in HPV Immunization
The partnership in Indonesia follows significant developments in China’s own public health policy regarding the virus. On 31 October 2025, the World Health Organization congratulated China on its decision to include the HPV vaccine in its national immunization programme.
Starting 10 November 2025, China began rolling out free, two-dose bivalent HPV vaccinations administered six months apart. This programme is available to girls born on or after 10 November 2011 who have reached 13 years of age.
This policy shift in China was prompted by a heavy disease burden; in 2022, China reported 151,000 new cases and 56,000 deaths from cervical cancer, representing nearly one in five cases worldwide.
Martin Taylor, the WHO Representative in China, described the inclusion of the vaccine in the national programme as a breakthrough for women’s health in China and a powerful boost to global momentum to end cervical cancer.
Impact of Early Vaccination
Medical evidence from various countries indicates that introducing the HPV vaccine during early adolescence dramatically reduces the occurrence of infections and precancerous lesions.
By targeting younger populations, public health initiatives aim to establish a strong foundation for future protection and move closer to making cervical cancer a disease of the past.
The expansion of access through the China-Indonesia partnership seeks to mirror these successes by removing the financial and logistical barriers that have previously prevented Indonesian women and girls from receiving life-saving immunization.